Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.15)
# 515
Out of 4,996 analysts
79
Total ratings
53.57%
Success rate
15.19%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Outperform | $60 → $80 | $50.40 | +58.73% | 1 | Sep 3, 2025 | |
| VIR Vir Biotechnology | Initiates: Outperform | $12 | $5.49 | +118.58% | 1 | Sep 3, 2025 | |
| IMNM Immunome | Initiates: Outperform | $18 | $11.59 | +55.31% | 1 | Aug 22, 2025 | |
| SMMT Summit Therapeutics | Maintains: Outperform | $30 → $34 | $20.95 | +62.29% | 2 | Aug 12, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $55 | $37.98 | +44.81% | 1 | May 14, 2025 | |
| MRNA Moderna | Maintains: In-Line | $50 → $32 | $24.49 | +30.67% | 6 | May 2, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $190 → $185 | $142.00 | +30.28% | 2 | Apr 24, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $45 → $50 | $50.05 | -0.10% | 3 | Dec 23, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $45 → $50 | $16.05 | +211.53% | 2 | Dec 17, 2024 | |
| BNTX BioNTech SE | Upgrades: Outperform | $110 → $125 | $98.08 | +27.45% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $105 | $53.85 | +94.99% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,250 → $1,175 | $563.90 | +108.37% | 5 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $85 | $79.69 | +6.66% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $29.08 | +202.61% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $137.37 | +100.92% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $3.34 | +947.90% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $272.98 | -15.01% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $82.70 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $112.10 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $27.89 | -24.70% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $4.84 | +375.21% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $9.78 | +2,456.24% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.40 | +614.29% | 1 | Feb 14, 2018 |
Cytokinetics
Sep 3, 2025
Maintains: Outperform
Price Target: $60 → $80
Current: $50.40
Upside: +58.73%
Vir Biotechnology
Sep 3, 2025
Initiates: Outperform
Price Target: $12
Current: $5.49
Upside: +118.58%
Immunome
Aug 22, 2025
Initiates: Outperform
Price Target: $18
Current: $11.59
Upside: +55.31%
Summit Therapeutics
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $20.95
Upside: +62.29%
Xenon Pharmaceuticals
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $37.98
Upside: +44.81%
Moderna
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $24.49
Upside: +30.67%
Neurocrine Biosciences
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $142.00
Upside: +30.28%
BridgeBio Pharma
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $50.05
Upside: -0.10%
Edgewise Therapeutics
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $16.05
Upside: +211.53%
BioNTech SE
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $98.08
Upside: +27.45%
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $53.85
Upside: +94.99%
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $563.90
Upside: +108.37%
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $79.69
Upside: +6.66%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $29.08
Upside: +202.61%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $137.37
Upside: +100.92%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $3.34
Upside: +947.90%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $272.98
Upside: -15.01%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $82.70
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $112.10
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $27.89
Upside: -24.70%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $4.84
Upside: +375.21%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $9.78
Upside: +2,456.24%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.40
Upside: +614.29%